Enhanced osteoclastogenesis in patients with tophaceous gout: Urate crystals promote osteoclast development through interactions with stromal cells
Open Access
- 31 May 2008
- journal article
- gout
- Published by Wiley in Arthritis & Rheumatism
- Vol. 58 (6), 1854-1865
- https://doi.org/10.1002/art.23488
Abstract
Objective To analyze cellular mechanisms of bone erosion in gout. Methods Peripheral blood mononuclear cells (PBMCs) and synovial fluid mononuclear cells (SFMCs) from patients with gout were analyzed for the presence of osteoclast precursors. Fixed tophus and bone samples were analyzed by immunohistochemistry. Mechanisms of osteoclastogenesis were studied by culturing murine preosteoclast RAW 264.7 cells, bone marrow stromal ST2 cells, and human synovial fibroblasts with monosodium urate monohydrate (MSU) crystals. Results PBMCs from patients with severe erosive gout had the preferential ability to form osteoclast‐like cells in culture with RANKL and monocyte colony‐stimulating factor (M‐CSF). The number of PBMC‐derived tartrate‐resistant acid phosphatase (TRAP)–positive multinucleated cells strongly correlated with the number of tophi (r = 0.6296, P = 0.630). Patients with severe erosive and tophaceous gout also had higher circulating concentrations of RANKL and M‐CSF. Furthermore, greater numbers of TRAP‐positive multinucleated cells were cultured from SFMCs derived from gouty knee effusions than from paired PBMCs (P = 0.004). Immunohistochemical analysis demonstrated numerous multinucleated cells expressing osteoclast markers within tophi and at the interface between soft tissue and bone. MSU crystals did not directly promote osteoclast formation from RAW 264.7 cells in vitro. However, MSU crystals inhibited osteoprotegerin gene and protein expression in ST2 cells and human synovial fibroblasts, without significantly altering RANKL gene expression. Conditioned medium from ST2 cells cultured with MSU crystals promoted osteoclast formation from RAW 264.7 cells in the presence of RANKL. Conclusion Chronic tophaceous and erosive gout is characterized by enhanced osteoclast development. These data provide a rationale for the study of osteoclast‐targeted therapies for the prevention of bone damage in chronic gout.Keywords
This publication has 35 references indexed in Scilit:
- Tophaceous joint disease strongly predicts hand function in patients with goutRheumatology, 2007
- Validation of a radiographic damage index in chronic goutArthritis Care & Research, 2007
- MyD88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urate crystalsJournal of Clinical Investigation, 2006
- Mechanisms of spontaneous osteoclastogenesis in cancer with bone involvementThe FASEB Journal, 2004
- Proline‐rich tyrosine kinase 2 and Src kinase signaling transduce monosodium urate crystal–induced nitric oxide production and matrix metalloproteinase 3 expression in chondrocytesArthritis & Rheumatism, 2004
- Osteoclastic bone resorption in rheumatoid arthritis and the acute-phase responseRheumatology, 2003
- Characterization of osteoclast precursors in human bloodBritish Journal of Haematology, 2000
- Human osteoclasts derive from CD14‐positive monocytesBritish Journal of Haematology, 1999
- Human arthroplasty derived macrophages differentiate into osteoclastic bone resorbing cellsAnnals Of The Rheumatic Diseases, 1997
- Preliminary criteria for the classification of the acute arthritis of primary goutArthritis & Rheumatism, 1977